It's is a big prophecy to fulfil indeed. But it's an opinion...

It's is a big prophecy to fulfil indeed.

But it's an opinion formed on what I've seen & heard to date.

An opinion formed on the current IP/projects & the $14m cash on hand.

Forget the share price from a $1+ perspective because the market cap is what the real consideration should be.

PTX has a reasonably tight share register as it stands & is well funded so any new shares on issue are unlikely anytime soon, when they are issued it is likely the sp will be multiples of now with minimal dilution. So with a tight register the sp can move much faster and ptx seems way undervalued as a general consensus.

I think it's also important to take the target market into context, there doesn't seem to be half measures of success when these biotech companies make a break...It's very reasonable to expect the $1b mc to be broken on ptx-100 moving to a registrational trial should it happen (looking likely), when you add in the remaining suite of projects including the most lucrative in OmniCar potentially moving to trial next year than....

See how it all pans out.